



BLOOD & MARROW TRANSPLANT CLINICAL TRIALS NETWORK

20+ Years of Collaborative Research



Mission:
Evaluate promising transplantation and cellular therapies in multi-institutional clinical studies designed to improve the outcomes of patients facing life-threatening blood disorders

Improving Therapy. Saving Lives.


BMT CTN Data and Coordinating Center Leadership


- Principal Investigator, MCW
Scientific Director Emeritus, CIBMTR
Deputy Cancer Center Director, MCW
 - Mary Horowitz, MD, MS
- Co-Principal Investigator, NMDP
Chief Medical Officer
 - Steve Devine, MD
- Co-Principal Investigator, Emmes
Vice President
 - Adam Mendizabal, PhD
- Senior Statistician, MCW
Chief, Division of Biostatistics, MCW
 - Brent Logan, PhD




BMT CTN Data and Coordinating Center Leadership


- Principal Protocol Officer &
CIBMTR Scientific Director
 - Mehdi Hamadani, MD
- Project Director, Emmes
 - Iris Gersten, MS
- Program Manager, CIBMTR
 - Amy Foley, MA





BMT CTN Trials Developed in Years 1-10






BMT CTN Trials Developed in Years 11-21




- 58 Trials Opened; 9 currently open
- 47 BMT CTN-led; 11 NCI Group/PI-led (+)
- 3 released to sites/in development:
 - 1901 Myeloma CAR T Cell: High Risk
 - 2001 Williams Gene Therapy SCD
 - 2002 Acute GVHD Treatment-TGuard2

PUBLICATIONS

- ★ Primary Outcome
- ★ Safety, Secondary Outcome, or Design




- = Enrollment/follow-up complete
- = Enrollment complete; ongoing F/U
- = Enrollment on-going




BMT CTN Centers

>125 centers have enrolled >15,800 patients since 2003



BMT CTN Yearly and Cumulative Accrual to all Protocols, 2004-2021 >15,800 patients



BMT CTN: Addressing Important Issues in HCT

	Number of Studies	Number of Publications
GVHD Prevention, Treatment and Biology	12	27
Graft Sources for HCT	10	18
Conditioning/Maintenance/Comparison to non-HCT	10	17
Rare and Non-Malignant Diseases	10	9
Most Studies Include Assessments of Quality of Life, Biomarkers, Biology		

ORIGINAL ARTICLE

Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma

Philip L. McCarthy, M.D., Kouros Owzar, Ph.D., Craig C. Hofmann, M.D., David D. Hurd, M.D., Hani Hassoun, M.D., Paul G. Richardson, M.D., Sergio Giralt, M.D., Edward A. Stadtmauer, M.D., Daniel J. Weinstock, M.D.

Regular Article

CLINICAL TRIALS AND OBSERVATIONS

rapid communication

Impact of Conditioning Intensity of Allogeneic Transplantation for Acute Myeloid Leukemia: Genomic Evidence of Residual Disease

Christopher S. Hourigan, DM, DPhil¹; Laura W. Dillon, PhD¹; Gege Gui, ScM¹; Brent R. Logan, PhD²; Mi Jack Ghannam, BS¹; Yuesheng Li, PhD¹; Abel Licon, MS³; Edwin P. Alyea, MD⁴; Asad Bashey, MD⁵; H. Steven M. Devine, MD⁷; Hugo F. Fernandez, MD⁸; Sergio Giralt, MD⁹; Mehdi Hamadani, MD¹⁰; Alan Howard, MD¹¹; Richard T. Maziarz, MD¹¹; David L. Porter, MD¹²; Bart L. Scott, MD⁶; Erica D. Warlick, MD¹³; Marcelo C.

CLINICAL TRIALS AND OBSERVATIONS

Randomized multicenter trial of sirolimus vs prednisone as initial therapy for standard-risk acute GVHD: the BMT CTN 1501 trial

Joseph Bidele, 1 Mehdi Hamadani, 23 Peter Dawson, 4 Michael Martinez, 4 Alexis M. Aloufi, 5 Madan Jagasia, 6 Yuesheng Li, 7 Efstathios Kastritis, 8

CLINICAL TRIALS AND OBSERVATIONS

Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts

*Claudio G. Brunstein,¹ *Ephraim J. Fuchs,² Shelly L. Carter,³ Chatchada Karanes,⁴ Luciano J. Costa,⁵ Juan Wu,³ Steven M. Devine,⁶ John R. Wingard,⁷ Omar S. Aljaitawi,⁸ Corey S. Cutler,⁹ Madan H. Jagasia,¹⁰ Karen K. Ballen,¹¹ †Mary Eapen,¹² and †Paul V. O'Donnell,¹³ on behalf of the Blood and Marrow Transplant Clinical Trials Network

¹Blood and Marrow Transplant Program, University of Minnesota, Minneapolis, MN; ²Sidney Kimmel Cancer Center, Johns Hopkins University, Baltimore, MD;

³The Emma Children's Hospital, Amsterdam, The Netherlands; ⁴City of Hope National Medical Center, Duarte, CA; ⁵Medical University of South Carolina, Charleston, SC; ⁶The Ohio State University, Columbus, OH; ⁷University of Texas MD Anderson Cancer Center, Houston, TX; ⁸University of Illinois at Chicago, Chicago, IL; ⁹University of California, San Francisco, CA; ¹⁰University of Michigan, Ann Arbor, MI; ¹¹University of Texas at Austin, Austin, TX; ¹²University of California, Los Angeles, Los Angeles, CA; ¹³University of California, San Diego, San Diego, CA



Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes

Bart L. Scott, Marcelo C. Pasquini, Brent R. Logan, Juan Wu, Steven M. Devine, David L. Porter, Richard T. Maziarz, Erica D. Warlick, Hugo F. Fernandez, Edwin P. Alyea, Mehdi Hamadani, Asad Bashey, Sergio Giralt, Marcelo C. Pasquini

original research

Autologous Transplantation, Consolidation, and Maintenance Therapy in Multiple Myeloma: Results of the BMT CTN 0702 Trial

Presentation last saved: Just now



The NEW ENGLAND JOURNAL of MEDICINE

ESTABLISHED IN 1812

OCTOBER 18, 2012

VOL. 367 NO. 16

Peripheral-Blood Stem Cells versus Bone Marrow from Unrelated Donors

Claudio Anasetti, M.D., Brent R. Logan, Ph.D., Stephanie J. Lee, M.D., M.P.H., Edmund K. Waller, M.D., Ph.D., Daniel J. Weisdorf, M.D., John R. Wingard, M.D., Corey S. Cutler, M.D., M.P.H., Peter Westervelt, M.D., Ph.D., Ann Woolfrey, M.D., Stephen Couban, M.D., George A. Papanicolaou, M.D., David L. Porter, M.D., Paolo Anderlini, M.D., William I. Berenson, M.D., Christopher Bredeson, M.D., Shelly L. Carter, M.D., for the Blood and Marrow Transplant Clinical Trials Network

>140 BMT CTN Publications